E-ISSN 2602-3164
EJMI. 2022; 6(2): 203-209 | DOI: 10.14744/ejmi.2022.38962

Prognostic Factors in Advanced Pancreatic Cancer: Single-Center, Real-World Data

Eda Tanrikulu Simsek1
1Department of Medical Oncology, Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey

Objectives: Eighty percent of patients with pancreatic cancer present with unresectable/metastatic disease. Although clinical trials evaluating the efficacy of systemic treatments have been conducted in selected patient groups, reported survivals are short. In our study, we aimed to evaluate real-life data and factors affecting survival in patients with unresectable/metastatic pancreatic cancer. Methods:The files of the patients who were followed up in our outpatient clinic with the diagnosis of pancreatic adenocarcinoma were evaluated retrospectively. A total of 151 patients had de-novo or recurrent, unresectable/metastatic disease. Variables that may affect the survival of these patients were recorded. Results: The median overall survival (OS) of patients receiving no systemic therapy for unresectable/metastatic disease and patients receiving chemotherapy was 2.4 months(m) and 9.3m, respectively (p <0.001). Patients with unresectable/metastatic disease had a median OS of 11.6 m and 8.9 m (p=0.02) for recurrent disease and de-novo disease, respectively. The median OS of patients with isolated lung metastases and other patients were 15.4m and 7.8m (p=0.02), respectively. Conclusion:In unresectable/metastatic pancreatic cancer, recurrent disease and isolated lung metastasis are good prognostic factors. These parameters can be used as stratification factors in prospective studies. Real-life survival data are in compliance with the literature. There is a need for new treatments to improve survival in pancreatic cancer, and studies to identify new markers that determine the course of the disease and can create targets in treatment. Keywords: Pancreatic Cancer, Survival, Pancreas, Recurrence, Chemotherapy

Cite This Article

Simsek E. Prognostic Factors in Advanced Pancreatic Cancer: Single-Center, Real-World Data. EJMI. 2022; 6(2): 203-209

Corresponding Author:

Full Text PDF PDF Download